CGTLive®’s Weekly Rewind – January 9, 2026

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401

The BLA is supported by 96-week data from the randomized, placebo-controlled phase 3 GlucoGene clinical trial.

2. Interview Highlights From ASH's 2025 Meeting

We showcased several key moments from our on the ground coverage of the 67th American Society of Hematology Annual Meeting and Exposition.

3. ImmunoLogic, Bonus Episode: "Chemo Optional, Data Mandatory - A Year-End Recap"

In this bonus episode of ImmunoLogic, the hosts discussed highlights from 2025, including some covered in previous episodes of the series.

4. Integrating AI Tools Into Clinical Practice for Genetic Counselors

Colleen Caleshu, MS, CGC, the senior director of research and real world data at Genome Medical, discussed important considerations for genetic counselors thinking about using AI tools in their practice.

5. FDA Decisions to Look For in 1H 2026

We highlighted a few cell and gene therapies that are nearing or likely nearing key FDA decisions in the first half of 2026.